Evaluation of Valvular Heart Disease Using Cardiac CT
Evaluation of Valvular Heart Disease: Multicenter Registry of Noninvasive Imaging Modalities by Cardiac CT
The EVIDENTIA Registry is a multicenter study designed to evaluate valvular heart disease (VHD) using cardiac CT. It aims to assess cardiac valve anatomy, function, and myocardial characteristics through detailed CT analysis.
- Assessing the accuracy of cardiac CT in evaluating cardiac structure, volume, function, and myocardium in VHD patients.
- Comparing the severity, classification, and etiology (primary vs. functional) of VHD.
- Monitoring serial changes in VHD severity via echocardiography.
- Investigating the relationship between echocardiographic and CT-derived parameters.
- Examining the correlation between imaging findings, VHD interventions, and patient prognosis.
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Hideki Koike, MD, PhD
- Phone Number: 81+3-3762-4151
- Email: hideki.koike@med.toho-u.ac.jp
Study Locations
-
-
Tokyo
-
Ota, Tokyo, Japan, 143-8540
- Recruiting
- Toho University
-
Contact:
- Ethics Committee of the Toho University
- Phone Number: 81+3-5763-6534
- Email: omori.rinri@ext.toho-u.ac.jp
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with at least moderate valvular heart disease who had a cardiac CT with 64 or more rows
- 18 years of age or older
Exclusion Criteria:
- Less than 18 years old
- Acute VHD
- Infectious endocarditis
- Patients with post-VHD intervention
- Poor CT image quality for analyzing CT data.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
the 1-year composite endpoint of all-cause death and major cardiac adverse events (MACE) including VHD intervention.
Time Frame: one year
|
one year
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- A24904
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.